We are a COVID-19 Testing Facility

Are you or a loved one living with Small Cell Lung Cancer?

A clinical study for adults diagnosed with Small Cell Lung Cancer
SEE IF YOU MAY QUALIFY

Why is the IMP4297 study being done?

The purpose of this study is to find out about the safety and tolerability of IMP4297 in combination with temozolomide to determine if it is an effective treatment for solid tumors. IMP4297 is experimental, which means it is not approved by Health Authorities including the U.S. Food and Drug Administration (FDA) for the treatment of solid tumors. Temozolomide is a chemotherapy drug that is approved by the FDA for the treatment of brain cancer. 

SEE IF YOU MAY QUALIFY

Who can participate in the IMP4297 study?

You may be eligible to participate in this study if you:

Are age 18 and older

Have been diagnosed with Extensive Stage Small Cell Lung Cancer

Have received one and only one course of 1L standard platinum-based therapy

  • Cisplatin
  • Carboplatin
  • Oxaliplatin
  • Nedaplatin
  • Lobaplatin
SEE IF YOU MAY QUALIFY

What happens during the study?

There are 5 study periods: screening, treatment, end of treatment, safety follow-up, and survival follow-up. All aspects of your participation will take place at the study location or at your place of residence. 

1

Screening:

  • You will have health checks and tests to confirm that you are eligible for the study.
  • You will be given an Informed Consent Form that contains all of the information about the study. This is to make sure that you understand the study and ask any questions you may have. If you agree to participate, you will give your permission by signing this form.
  • The screening period is up to 28-days before the first dose of the study drug.

2

Treatment

  • During the treatment period, eligible patients will receive the combination of IMP4297 and Temozolomide in 28-day cycles. The treatment period will continue until unacceptable adverse events, documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study (whichever occurs first).
  • The study medication will be taken daily by mouth.

3

End of Treatment:

  • The end of treatment visit will be 0-7 days after the last dose date. The end of treatment is the date in which the patient has permanently terminated the study treatment.

4

Safety Follow-Up:

  • 30 days after the last dose

5

Survival Follow-Up:

  • Every 12 weeks

What treatment will I receive?

You will receive both IMP4297 and Temozolomide daily by mouth.

  • IMP4297 will be administered daily on days 1-28
  • Temozolomide will be administered daily on days 1-21 (Temozolomide will not be administered on days 22-28)
SEE IF YOU MAY QUALIFY

What tests will I have?

During the study, you may have tests to assess:

  • Blood
  • Heart Activity
  • Urine
  • Medical Imaging

What else will I have to do?

Follow the study staff’s directions regarding the study

  • Complete all study visits.
  • Tell the study doctor if you have any health updates or changes in medication.
SEE IF YOU MAY QUALIFY

Will I receive compensation for participating in this study?

Yes, you will receive $150 upon your completion of the screening visit and $50 for each subsequent visit.

SEE IF YOU MAY QUALIFY






9730 S. Western Ave., Suite 218
Evergreen Park, IL 60805
872-205-3194

  • 9730 S. Western Ave., Suite 218 Evergreen Park, IL 60805
  • 872-205-3194

Clinical Trials

Clinical Research History
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Post Covid-19
COPD Clinical Study
Clinical Research History
NSCLC (EFGR/MET)

Social Links

Copyright © 2022 Gen Harp. All Rights Reserved
Design By INTIDOT